Moreover, regression analyses on a study conducted on European subjects (N = 270), with mild to severe AD, in AddNeuroMed studies and the Alzheimer’s Research Trust cohort and Kings College London (KCL-ART) cohort predicted cognitive decline over the subsequent 6 months [90], suggesting the potential of plasma TTR to serve as a biomarker of the progression and severity of AD. The gene discussed is TTR; the disease is Alzheimer disease.